Japanese Site 1
Multiple Locations, Japan
Location status: Recruiting
NCT Number: NCT07746544
The main purpose of this study is to compare secutrelvir to placebo with respect to resolution of clinical symptoms in nonhospitalized participants with Coronavirus Disease 2019 (COVID-19) starting intervention within 48 hours of COVID-19 symptom onset.
Interested in participating?
Request Info12 year–74 year
All sexes
Interventional
Phase 3
Multiple Locations, Japan
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined inclusion and exclusion criteria may apply.
Secutrelvir will be administered orally as a tablet.
Other names: S-892216
Placebo will be administered orally as a tablet.
Time frame: Baseline through Day 21
Symptoms will be assessed by the investigator via a participant daily electronic diary.
Time frame: Baseline through Day 28
Symptoms will be assessed by the investigator via a participant daily electronic diary.
Time frame: Baseline through Day 21
Symptoms will be assessed by the investigator via a participant daily electronic diary.
Time frame: Baseline through Day 28
Symptoms will be assessed by the investigator via a participant daily electronic diary.
Time frame: Baseline through Day 21
Symptoms will be assessed by the investigator via a participant daily electronic diary.
Time frame: Baseline through Day 21
Symptoms will be assessed by the investigator via a participant daily electronic diary.
Time frame: Baseline, Day 8
Time frame: Baseline through Day 28
Symptoms will be assessed by the investigator via a participant daily electronic diary.
Time frame: Baseline through Day 28
Symptoms will be assessed by the investigator via a participant daily electronic diary
Time frame: Baseline through Day 28
Time frame: Baseline through Day 21
Time frame: Baseline through Day 21
Time frame: Days 4 and 8
Time frame: Baseline through Day 28
Contact information is provided by the study sponsor or research team.
Shionogi Clinical Trials Administrator Clinical Support Help Line
CONTACT
Shionogi
Industry
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Secutrelvir in Participants With COVID-19
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01306084
Adenoviridae Infections, Anogenital Herpes
Bethesda, Maryland, United States
View Trial DetailsNCT07536308
COVID-19, Coronaviridae Infections
Decatur, Georgia, United States
View Trial DetailsNCT06417762
Behavior, COVID-19
Chicago, Illinois, United States
View Trial DetailsNCT06810934
COVID-19, Coronaviridae Infections
Los Angeles, California, United States
View Trial Details